OncNGS
  • Home
  • Call for tenders (closed)
  • About OncNGS
  • Phases
    • Pre-commercial Procedure
    • Phase 0 : Curiosity Driven Research
    • Open Market Consultation
    • Phase I : Solution design
    • Phase II: Prototype development
    • Phase III : Clinical validation of a limited set of pre-commercial devices
  • FAQ
  • News
  • Contact
  • Workspace
  • Home
  • Call for tenders (closed)
  • About OncNGS
  • Phases
    • Pre-commercial Procedure
    • Phase 0 : Curiosity Driven Research
    • Open Market Consultation
    • Phase I : Solution design
    • Phase II: Prototype development
    • Phase III : Clinical validation of a limited set of pre-commercial devices
  • FAQ
  • News
  • Contact
  • Workspace

Phase 0 : Curiosity Driven Research

During this phase of the project, the oncNGS consortium will work on the definitions of the needs and their translation into the tender requirements and specifications.

In the Phase 0 will be organized an Open Market Consultation (OMC) in which the scope of the oncNGS pre-commercial procurement will be refined through a dialogue with potential suppliers and other stakeholders. The OMC will help us to collect insight into the market, including the state of the art and current developments. The outcome of this phase will be the preparation of a Call for Tender (CfT). The CfT will remain open for submission of tenders for at least 60 days. OncNGS CfT shall be open to any interested suppliers, with no need for a special invitation or specific pre-qualification requirements.

The pre-commercial procurement procedure consists of three clearly defined phases: Solution design, Prototype development and Clinical validation of a limited scale pre-commercial devices (see graphic above).

Phases of OncNGS PCP

 

Other phases

Pre-commercial procedure
Phase I : Solution Design
Phase II : Prototype development
Phase III : Clinical validation of a limited set of pre-commercial devices

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 874467

Follow us:

© OncNGS

  • Privacy policy
  • Disclaimer